AMARIN CORP PLC\UK Unrecognized Tax Benefits, Income Tax Penalties Expense
AMARIN CORP PLC\UK (AMRN) reported Unrecognized Tax Benefits, Income Tax Penalties Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties › Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense · last filed 2026-03-02
- AMARIN CORP PLC\UK unrecognized tax benefits, income tax penalties expense for fiscal 2025 was $0.00.
- AMARIN CORP PLC\UK unrecognized tax benefits, income tax penalties expense for fiscal 2024 was $0.00.
- AMARIN CORP PLC\UK unrecognized tax benefits, income tax penalties expense for fiscal 2023 was $0.00.
- AMARIN CORP PLC\UK unrecognized tax benefits, income tax penalties expense for fiscal 2022 was $0.00.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties Expense 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-02 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-02 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-12 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-29 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-01 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |